[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 21 of about 21
1. Martínez-León MI, Weil-Lara B, Herrero-Hernández A: [Papilloma and carcinoma of the choroid plexus in pediatric patients]. Radiologia; 2007 Jul-Aug;49(4):279-86
Genetic Alliance. consumer health - Choroid Plexus Papilloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Papilloma and carcinoma of the choroid plexus in pediatric patients].
  • Papillomas of the choroid plexus are rare tumors of neuroectodermal origin; they represent less than 5% of all central nervous system (CNS) tumors in pediatric patients.
  • Choroid plexus carcinomas are even rarer.
  • We reviewed the incidence of these neoplasms at our reference hospital and found six tumors of the choroid plexus (five papillomas and one carcinoma) in five patients.
  • All five patients underwent computed tomography (CT) examination.
  • All patients had tumors located in the lateral ventricles, and one patient had a second tumor located in the third ventricle.
  • All patients underwent surgery; total resection was achieved in the five papillomas, whereas the carcinoma was partially resected and the patient is currently undergoing chemotherapy.
  • The patient with two papillomas shows good recovery at follow-up, whereas the patient with carcinoma of the choroid plexus has a poor prognosis.
  • [MeSH-major] Carcinoma. Choroid Plexus Neoplasms. Papilloma

  • Genetic Alliance. consumer health - Choroid Plexus Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17594892.001).
  • [ISSN] 0033-8338
  • [Journal-full-title] Radiología
  • [ISO-abbreviation] Radiologia
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


2. Wrede B, Hasselblatt M, Peters O, Thall PF, Kutluk T, Moghrabi A, Mahajan A, Rutkowski S, Diez B, Wang X, Pietsch T, Kortmann RD, Paulus W, Jeibmann A, Wolff JEA: Atypical choroid plexus papilloma: clinical experience in the CPT-SIOP-2000 study. J Neurooncol; 2009 Dec;95(3):383-392
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical choroid plexus papilloma: clinical experience in the CPT-SIOP-2000 study.
  • Atypical choroid plexus papilloma (APP) represents a novel intermediate-grade subtype of choroid plexus tumor (CPT), the clinical outcome of which has not been described yet.
  • A worldwide registration and a randomized trial for those patients who require chemotherapy started in 2000.
  • After surgery, patients who had undergone complete resection were observed, whereas patients with incompletely resected or metastasized APP were treated with six chemotherapy courses (etoposide and vincristine, combined with either carboplatin or cyclophosphamide).
  • All nine APP patients who received postoperative chemotherapy showed an early response after two cycles: two had complete remission, four had partial response, and three had stable disease.
  • In the treatment group, one patient with a metastasized tumor and incompletely resected APP died.
  • While APP was defined histologically, median percentages of both the Ki-67/MIB-1 proliferation marker and the p53 tumor suppressor protein increased across the three histological subtypes (from CPP to APP and then CPC), suggesting that the subtypes comprise an ordinal categorization of increasingly severe CPT tumors.
  • APP responded favorably to chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Choroid Plexus Neoplasms / drug therapy. Choroid Plexus Neoplasms / mortality. Papilloma, Choroid Plexus / drug therapy. Papilloma, Choroid Plexus / mortality
  • [MeSH-minor] Adolescent. Adult. Carboplatin / administration & dosage. Child, Preschool. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Etoposide / administration & dosage. Female. Gadolinium. Humans. Infant. Kaplan-Meier Estimate. Magnetic Resonance Imaging. Male. Middle Aged. Registries. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Choroid Plexus Papilloma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Neurosurg. 1999 Sep;31(3):127-30 [10708353.001]
  • [Cites] J Neurooncol. 2000 Sep;49(3):263-8 [11212906.001]
  • [Cites] J Neurooncol. 2007 Dec;85(3):345-51 [17576522.001]
  • [Cites] Med Pediatr Oncol. 1993;21(7):480-7 [8341215.001]
  • [Cites] J Neurosurg. 2007 Sep;107(3 Suppl):199-202 [17918524.001]
  • [Cites] Lancet. 1999 Jun 19;353(9170):2126 [10382700.001]
  • [Cites] J Neurooncol. 2002 Feb;56(3):241-6 [12061730.001]
  • [Cites] Cancer. 1992 Jan 15;69(2):580-5 [1728390.001]
  • [Cites] J Neurosurg. 1998 Apr;88(4):757-60 [9525724.001]
  • [Cites] J Neurooncol. 1985;3(3):259-62 [2414413.001]
  • [Cites] J Neurooncol. 2004 May;68(1):49-55 [15174521.001]
  • [Cites] Surg Neurol. 1991 Jul;36(1):54-8 [2053075.001]
  • [Cites] Pediatr Neurosci. 1989;15(4):195-206 [2485914.001]
  • [Cites] Pediatr Neurosurg. 1991-1992;17(5):225-33 [1822687.001]
  • [Cites] J Neurooncol. 2007 Mar;82(1):69-74 [16955222.001]
  • [Cites] Anticancer Res. 2005 Nov-Dec;25(6C):4429-33 [16334121.001]
  • [Cites] Indian Pediatr. 1993 Oct;30(10):1217-8 [8077013.001]
  • [Cites] Acta Neurochir (Wien). 1979;50(1-2):79-90 [316268.001]
  • [Cites] Neuropathology. 2008 Apr;28(2):160-4 [18366349.001]
  • [Cites] Acta Neurochir (Wien). 1996;138(7):802-10 [8869707.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Microsc Res Tech. 2001 Jan 1;52(1):104-11 [11135453.001]
  • [Cites] Neuropathology. 2009 Jun;29(3):293-8 [18627486.001]
  • [Cites] Neurol Med Chir (Tokyo). 1995 Oct;35(10):742-4 [8532130.001]
  • [Cites] Acta Neuropathol. 2002 Jan;103(1):1-10 [11837741.001]
  • [Cites] J Neurosurg Spine. 2006 Jun;4(6):494-6 [16776361.001]
  • [Cites] Pediatr Neurosurg. 1995;22(4):189-96 [7619719.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Nov;65(11):1069-73 [17086103.001]
  • [Cites] Neurosurgery. 1998 Mar;42(3):470-5 [9526979.001]
  • [Cites] J Neurosurg. 2004 Jun;100(6):1076-8 [15200124.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Pediatr Neurosurg. 2000 Apr;32(4):192-9 [10940770.001]
  • [Cites] J Neurosurg. 1980 Feb;52(2):251-5 [7351566.001]
  • [Cites] J Neurosurg. 1988 Dec;69(6):843-9 [3193190.001]
  • [Cites] Br J Cancer. 2002 Nov 4;87(10):1086-91 [12402146.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 May;56(5):551-6 [9143268.001]
  • [Cites] Neuropathol Appl Neurobiol. 2004 Jun;30(3):304-7 [15175083.001]
  • [Cites] Med Pediatr Oncol. 1995 Feb;24(2):104-8 [7990757.001]
  • [Cites] Neurosurgery. 1989 Sep;25(3):327-35 [2771002.001]
  • [Cites] Acta Neurochir (Wien). 2007 Dec;149(12):1229-36; discussion 1236-7 [17924056.001]
  • [Cites] Am J Surg Pathol. 2006 Jan;30(1):66-74 [16330944.001]
  • [Cites] Histopathology. 1996 Aug;29(2):147-51 [8872148.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 May;64(5):391-7 [15892296.001]
  • [Cites] J Neurosurg. 1998 Mar;88(3):521-8 [9488307.001]
  • [Cites] Childs Nerv Syst. 1989 Oct;5(5):288-98 [2804999.001]
  • (PMID = 19543851.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00500890
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / R01 CA083932
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; AU0V1LM3JT / Gadolinium; BG3F62OND5 / Carboplatin
  •  go-up   go-down


3. Gururangan S, Petros WP, Poussaint TY, Hancock ML, Phillips PC, Friedman HS, Bomgaars L, Blaney SM, Kun LE, Boyett JM: Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004). Clin Cancer Res; 2006 Mar 1;12(5):1540-6
Hazardous Substances Data Bank. BUSULFAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004).
  • PURPOSE: A phase I trial of intrathecal Spartaject Busulfan (SuperGen, Inc., San Ramon, CA) was conducted in children with neoplastic meningitis following recurrent primary brain tumors to describe toxicities, estimate the maximum tolerated dose (MTD), and document evidence of responses to this agent.
  • Patients with stable disease or an objective response continued to receive intrathecal Spartaject Busulfan plus systemic chemotherapy at regular intervals.
  • CONCLUSIONS: Intrathecal Spartaject Busulfan was well tolerated in children with neoplastic meningitis from brain tumors, and the recommended dose for future phase II studies is 13 mg.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Busulfan / therapeutic use. Meningeal Neoplasms / drug therapy. Meningitis / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Choroid Plexus Neoplasms / blood. Choroid Plexus Neoplasms / cerebrospinal fluid. Choroid Plexus Neoplasms / drug therapy. Cohort Studies. Ependymoma / blood. Ependymoma / cerebrospinal fluid. Ependymoma / drug therapy. Female. Glioma / blood. Glioma / cerebrospinal fluid. Glioma / drug therapy. Humans. Injections, Spinal. Male. Maximum Tolerated Dose. Neuroectodermal Tumors, Primitive / blood. Neuroectodermal Tumors, Primitive / cerebrospinal fluid. Neuroectodermal Tumors, Primitive / drug therapy

  • MedlinePlus Health Information. consumer health - Meningitis.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16533779.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5 U01 CA081457
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; G1LN9045DK / Busulfan
  •  go-up   go-down


Advertisement
4. Lafay-Cousin L, Mabbott DJ, Halliday W, Taylor MD, Tabori U, Kamaly-Asl ID, Kulkarni AV, Bartels U, Greenberg M, Bouffet E: Use of ifosfamide, carboplatin, and etoposide chemotherapy in choroid plexus carcinoma. J Neurosurg Pediatr; 2010 Jun;5(6):615-21
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of ifosfamide, carboplatin, and etoposide chemotherapy in choroid plexus carcinoma.
  • OBJECT: Choroid plexus carcinomas (CPCs) are rare pediatric tumors with a generally poor prognosis.
  • Although the role of surgery is well recognized, the role of adjuvant chemotherapy and radiation therapy remains unclear.
  • In this paper, the authors' goal was to assess the role of second-look surgery and neoadjuvant ifosfamide, carboplatin, etoposide (ICE) chemotherapy in the management of CPC and to study neurocognitive outcome.
  • Two of the 14 patients underwent gross-total resection during initial surgery; 12 of the patients received neoadjuvant chemotherapy, 10 of whom underwent second surgery.
  • In total, of 12 patients who received chemotherapy with a curative intent, 11 underwent a greater than 95% resection.
  • Neoadjuvant ICE chemotherapy was given prior to second surgery (median 4 cycles, range 2-5 cycles) and was continued after second resection for a median total of 7 cycles (range 4-16 cycles).
  • RESULTS: No tumor progression was observed during chemotherapy prior to second surgery.
  • Five patients subsequently experienced tumor progression/relapse.
  • None of the survivors received radiation therapy.
  • CONCLUSIONS: In this experience, second surgery following neoadjuvant ICE chemotherapy led to a high rate of complete or near-complete resection.
  • Chemotherapy appears to facilitate second-look surgery, in particular through a reduction of intraoperative blood loss.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Choroid Plexus Neoplasms / drug therapy. Choroid Plexus Neoplasms / surgery. Neoadjuvant Therapy
  • [MeSH-minor] Brain Damage, Chronic / etiology. Carboplatin / administration & dosage. Child, Preschool. Cognition Disorders / etiology. Drug Administration Schedule. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. Infant. Kaplan-Meier Estimate. Male. Postoperative Complications / etiology. Reoperation. Retrospective Studies

  • Genetic Alliance. consumer health - Choroid Plexus Carcinoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20515336.001).
  • [ISSN] 1933-0715
  • [Journal-full-title] Journal of neurosurgery. Pediatrics
  • [ISO-abbreviation] J Neurosurg Pediatr
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide; ICE protocol 3
  •  go-up   go-down


5. Fiorillo A, Maggi G, Cirillo S, Migliorati R, Buffardi F, Alfieri E, Sabbatino MS, D'Amico A, DelBasso DeCaro ML: Efficacy of sequential chemotherapy including methotrexate and doxorubicin in an infant with partially resected choroid plexus carcinoma. Pediatr Neurosurg; 2003 Jan;38(1):21-6
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of sequential chemotherapy including methotrexate and doxorubicin in an infant with partially resected choroid plexus carcinoma.
  • This report refers to a 3-month-old male, with a residual choroid plexus carcinoma following partial resection, who was successfully treated with sequential chemotherapy without any postoperative radiation therapy.
  • Along with carboplatin, we also used doxorubicin and methotrexate, hypothesizing that, given the patient's age, the blood-brain barrier should not hamper drug delivery to the tumor.
  • According to this hypothesis, the treatment achieved complete remission of the disease, which lasts 27 months after the diagnosis.
  • This result deserves further studies to assess the possible curative role of chemotherapy in very young patients suffering from choroid plexus carcinoma.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Carboplatin / therapeutic use. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / surgery. Choroid Plexus Neoplasms / drug therapy. Choroid Plexus Neoplasms / surgery. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Methotrexate / administration & dosage. Methotrexate / therapeutic use

  • Genetic Alliance. consumer health - Choroid Plexus Carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger AG, Basel
  • (PMID = 12476023.001).
  • [ISSN] 1016-2291
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 80168379AG / Doxorubicin; BG3F62OND5 / Carboplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


6. Kellie SJ, Koopmans P, Earl J, Nath C, Roebuck D, Uges DR, De Graaf SS: Increasing the dosage of vincristine: a clinical and pharmacokinetic study of continuous-infusion vincristine in children with central nervous system tumors. Cancer; 2004 Jun 15;100(12):2637-43
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increasing the dosage of vincristine: a clinical and pharmacokinetic study of continuous-infusion vincristine in children with central nervous system tumors.
  • BACKGROUND: Vincristine (VCR) is widely used to treat patients with malignant disease; among the patients treated with VCR are children with brain tumors.
  • Therefore, the authors explored the neurotoxicity and pharmacokinetics of VCR administered via a 96-hour continuous infusion after administration of a conventional bolus dose in a pediatric population.
  • The diagnoses included intrinsic pontine glioma (n = 4), ependymoma (n = 5), astrocytoma (n = 3), medulloblastoma/primitive neuroectodermal tumor (PNET; n = 2), ganglioglioma (n = 1), and choroid plexus carcinoma (n = 1).
  • Treatment included cyclophosphamide 65 mg/kg administered intravenously over 1 hour on Day 1, a bolus of VCR 1.5 mg/m(2) administered intravenously on Day 2, and VCR 0.5 mg/m(2) per 24 hours administered via continuous intravenous infusion on Days 2-5.
  • Fifteen patients received 2 courses of treatment at 21-28-day intervals, and a total of 31 treatment courses were administered.
  • CONCLUSIONS: Continuous infusion of VCR after a conventional bolus dose plus cyclophosphamide for children with tumors of the central nervous system did not result in significant neurotoxicity and appeared to be a safe strategy for achieving increased systemic exposure.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Cyclophosphamide / administration & dosage. Vincristine / administration & dosage. Vincristine / pharmacokinetics
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Humans. Infant. Infusions, Intravenous. Male. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 American Cancer Society.
  • (PMID = 15197807.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


7. Broniscer A, Ke W, Fuller CE, Wu J, Gajjar A, Kun LE: Second neoplasms in pediatric patients with primary central nervous system tumors: the St. Jude Children's Research Hospital experience. Cancer; 2004 May 15;100(10):2246-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second neoplasms in pediatric patients with primary central nervous system tumors: the St. Jude Children's Research Hospital experience.
  • BACKGROUND: Details on second neoplasms (SNs) following pediatric central nervous system (CNS) tumors are scant, because of the rarity of such SNs.
  • METHODS: The authors reviewed clinical and treatment data on all institutional patients age < 22 years at diagnosis of a primary CNS tumor who developed any type of SN.
  • Patients with neurofibromatosis type 1 were excluded.
  • Twenty-one patients had previously received radiotherapy, and 12 patients had received chemotherapy.
  • Children with choroid plexus tumors had an estimated 10-year cumulative incidence rate of 20.2%; 2 of those patients had germline TP53 mutations.
  • No significant difference in the estimated cumulative incidence of SNs was found among patients who had received different types of therapy.
  • CONCLUSIONS: The risk of lethal SNs after pediatric CNS tumors is small.
  • Young patients and patients with choroid plexus tumors appear to have an increased risk of SNs that is associated with genetic factors.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / secondary. Neoplasms, Second Primary / pathology. Spinal Cord Neoplasms / pathology. Spinal Cord Neoplasms / secondary
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Incidence. Infant. Male. Radiotherapy. Retrospective Studies. Risk Factors. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 American Cancer Society.
  • (PMID = 15139071.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA21765
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


8. Kieran MW, Supko JG, Wallace D, Fruscio R, Poussaint TY, Phillips P, Pollack I, Packer R, Boyett JM, Blaney S, Banerjee A, Geyer R, Friedman H, Goldman S, Kun LE, Macdonald T, Pediatric Brain Tumor Consortium: Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors. Pediatr Blood Cancer; 2009 Feb;52(2):169-76
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors.
  • A phase I dose escalation study stratified by concurrent use (stratum II) or absence (stratum I) of enzyme-inducing anticonvulsant drugs was undertaken to estimate the maximum-tolerated dose (MTD) and to describe the toxicity profile of SU5416 in pediatric patients with refractory brain tumors.
  • Tumor types included 23 glial tumors, 4 neural tumors, 4 ependymomas, and 2 choroid plexus carcinomas.
  • The most serious drug-related toxicities were grade 3 liver enzyme abnormalities, arthralgia, and hallucinations.
  • The plasma pharmacokinetics of SU5416 was not significantly affected by the concurrent administration of enzyme-inducing anticonvulsant drugs.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2798-805 [12231519.001]
  • [Cites] Neoplasia. 2003 Mar-Apr;5(2):155-60 [12659688.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Jun;305(3):833-9 [12626639.001]
  • [Cites] Cell Mol Life Sci. 2003 Apr;60(4):794-802 [12785726.001]
  • [Cites] Am J Ophthalmol. 2003 Jul;136(1):194-6 [12834696.001]
  • [Cites] Lancet Neurol. 2003 Jul;2(7):404-9 [12849118.001]
  • [Cites] Blood. 2003 Aug 1;102(3):795-801 [12649163.001]
  • [Cites] Neurosurgery. 2003 Sep;53(3):639-60; discussion 660-1 [12943581.001]
  • [Cites] Clin Cancer Res. 2003 Aug 15;9(9):3369-75 [12960124.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2763-7 [12843001.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4772-81 [14581348.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Jan;53(1):39-42 [14551735.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):88-95 [14734456.001]
  • [Cites] Oncol Res. 2004;14(4-5):175-225 [14977353.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3365-70 [15161690.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4048-54 [15217937.001]
  • [Cites] Urol Oncol. 2004 May-Jun;22(3):193-6 [15271314.001]
  • [Cites] Clin Cancer Res. 2004 Sep 1;10(17):5732-40 [15355900.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Nov 12;324(2):471-80 [15474452.001]
  • [Cites] Br J Cancer. 2004 Sep 13;91(6):1174-80 [15305185.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] Chem Pharm Bull (Tokyo). 1985 Apr;33(4):1620-32 [4042238.001]
  • [Cites] J Biopharm Stat. 1997 Mar;7(1):171-8 [9056596.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):99-106 [9892193.001]
  • [Cites] Clin Cancer Res. 1997 Aug;3(8):1261-6 [9815808.001]
  • [Cites] Lung Cancer. 2004 Dec;46(3):283-91 [15541812.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Mar;55(3):295-300 [15538570.001]
  • [Cites] Br J Cancer. 2005 Oct 17;93(8):876-83 [16222321.001]
  • [Cites] Am J Clin Oncol. 2006 Apr;29(2):109-15 [16601426.001]
  • [Cites] Int J Cancer. 2006 Jul 15;119(2):423-31 [16477628.001]
  • [Cites] Leuk Lymphoma. 2006 Dec;47(12):2601-9 [17169805.001]
  • [Cites] Drug Metab Dispos. 2000 Dec;28(12):1505-12 [11095590.001]
  • [Cites] Blood. 2001 Jul 1;98(1):241-3 [11418488.001]
  • [Cites] Kobe J Med Sci. 2001 Aug;47(4):181-91 [11733657.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1657-67 [11896117.001]
  • [Cites] Ophthalmology. 2002 Sep;109(9):1745-51 [12208726.001]
  • [Cites] Invest New Drugs. 2007 Apr;25(2):165-72 [16983506.001]
  • (PMID = 19065567.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA081457-07; United States / NCI NIH HHS / CA / U01 CA081457; United States / NCI NIH HHS / CA / U01 CA081457-07; United States / NCI NIH HHS / CA / U01 CA81457
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Anticonvulsants; 0 / Indoles; 0 / Protein Kinase Inhibitors; 0 / Pyrroles; 71IA9S35AJ / Semaxinib; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  • [Other-IDs] NLM/ NIHMS124020; NLM/ PMC2775441
  •  go-up   go-down


9. Gopal P, Parker JR, Debski R, Parker JC Jr: Choroid plexus carcinoma. Arch Pathol Lab Med; 2008 Aug;132(8):1350-4
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for choroid plexus carcinoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Choroid plexus carcinoma.
  • Choroid plexus carcinoma is an uncommon neoplasm of the central nervous system most commonly found in the pediatric population.
  • Accurate histopathologic diagnosis is imperative, and this neoplasm should always be included in the differential diagnosis of a papillary intraventricular tumor.
  • Histopathologic features include blurring of papillary architecture, layers of neoplastic choroid plexus epithelial cells with pleomorphic nuclei, increased nuclear-to-cytoplasmic ratio, increased mitotic activity, areas of necrosis, and brain invasion.
  • Current accepted treatment is gross total surgical resection of the tumor as the goal.
  • Use of adjuvant chemotherapy is controversial at this time; however, it is considered in some cases.
  • [MeSH-major] Carcinoma. Choroid Plexus Neoplasms
  • [MeSH-minor] Carcinoma, Papillary / pathology. Cerebral Ventricle Neoplasms / pathology. Chemotherapy, Adjuvant. Choroid Plexus / pathology. Diagnosis, Differential. Epithelial Cells / pathology. Humans. Necrosis. Neoplasm Invasiveness. Prognosis

  • Genetic Alliance. consumer health - Choroid Plexus Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Pathol Lab Med. 2009 May;133(5):680 [19415940.001]
  • (PMID = 18684041.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 30
  •  go-up   go-down


10. Jennings MT, Cmelak A, Johnson MD, Moots PL, Pais R, Shyr Y: Differential responsiveness among "high risk" pediatric brain tumors in a pilot study of dose-intensive induction chemotherapy. Pediatr Blood Cancer; 2004 Jul;43(1):46-54
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential responsiveness among "high risk" pediatric brain tumors in a pilot study of dose-intensive induction chemotherapy.
  • BACKGROUND: These factors have been predictive for progressive disease on therapy (PDOT) among pediatric brain tumors: >1.5 cm(2) unresectable tumor, glioblastoma, supratentorial primitive neuroectodermal tumor, and metastatic medulloblastoma (MBL).
  • Maintenance chemotherapy consisted of eight cycles of carboplatin, etoposide, and vincristine.
  • RESULTS: Twenty newly diagnosed patients [nine primitive neuroectodermal tumors/MBL, one choroid plexus carcinoma, eight malignant gliomas, and two anaplastic ependymomas] were treated.
  • Induction chemotherapy produced partial and minor responses (MRs) among 5/10.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Glioma / drug therapy. Neuroectodermal Tumors, Primitive / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Disease-Free Survival. Dose Fractionation. Etoposide / administration & dosage. Female. Humans. Male. Neoadjuvant Therapy. Pilot Projects. Statistics, Nonparametric. Survival Rate. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • (PMID = 15170889.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


11. Karami KJ, Poulik J, Rabah R, Krass J, Sood S: Simultaneous choroid plexus carcinoma and pilocytic astrocytoma in a pediatric patient. J Neurosurg Pediatr; 2010 Jan;5(1):104-12
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous choroid plexus carcinoma and pilocytic astrocytoma in a pediatric patient.
  • Simultaneous primary brain tumors in pediatric patients without prior chemotherapy or radiotherapy, phacomatosis, or known familial history are a rare occurrence.
  • The authors report the case of a 4-year-old boy with simultaneous choroid plexus carcinoma and pilocytic astrocytoma with features of oligodendroglioma.
  • Magnetic resonance imaging studies revealed diffuse heterogeneously enhancing left intraventricular and posterior fossa tumors initially believed most consistent with multicentric choroid plexus carcinomas.
  • A multiple staged resection was carried out for each tumor and gross-total resection was achieved.
  • Upon gross inspection intraoperatively as well as postoperative histological analysis, 2 distinct simultaneous tumors were identified: choroid plexus carcinoma and pilocytic astrocytoma.
  • To the authors' knowledge this is the first case report published identifying 2 distinct tumor types with similar radiological appearances in a pediatric patient with no prior history of radiotherapy, chemotherapy, or phacomatosis.
  • [MeSH-major] Astrocytoma / diagnosis. Astrocytoma / surgery. Cerebral Ventricle Neoplasms / diagnosis. Cerebral Ventricle Neoplasms / surgery. Choroid Plexus Neoplasms / diagnosis. Choroid Plexus Neoplasms / surgery. Fourth Ventricle / surgery. Lateral Ventricles / surgery. Magnetic Resonance Imaging. Neoplasms, Multiple Primary / diagnosis. Neoplasms, Multiple Primary / surgery. Neuronavigation. Thalamus / surgery. Tomography, X-Ray Computed


12. Postovsky S, Vlodavsky E, Eran A, Guilburd J, Ben Arush MW: Secondary glioblastoma multiforme after treatment for primary choroid plexus carcinoma in childhood. J Pediatr Hematol Oncol; 2007 Apr;29(4):248-52
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary glioblastoma multiforme after treatment for primary choroid plexus carcinoma in childhood.
  • A 15-year-old boy was diagnosed with choroid plexus carcinoma (CPC) of the right lateral ventricle.
  • After complete macroscopic resection of the tumor, the patient was treated with chemotherapy consisting of vincristine, cisplatin, etoposide, and carboplatin, followed by radiotherapy for a total dose of 34.2 Gy on the whole craniospinal axis plus a boost of 19.8 Gy at the tumor region.
  • The patient remained in complete clinical and radiologic remission over the next 5 years when a secondary malignant tumor, glioblastoma multiforme, a rare complication of the treatment of CPC, was diagnosed.
  • [MeSH-major] Choroid Plexus Neoplasms / pathology. Glioblastoma / pathology. Neoplasms, Second Primary / pathology
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carboplatin / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Diagnosis, Differential. Etoposide / administration & dosage. Fatal Outcome. Humans. Male. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Choroid Plexus Carcinoma.
  • Genetic Alliance. consumer health - Glioblastoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17414567.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


13. Dickens DS, Dothage JA, Heideman RL, Ballard ET, Jubinsky PT: Successful treatment of an unresectable choroid plexus carcinoma in a patient with Li-Fraumeni syndrome. J Pediatr Hematol Oncol; 2005 Jan;27(1):46-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of an unresectable choroid plexus carcinoma in a patient with Li-Fraumeni syndrome.
  • Choroid plexus carcinoma (CPC) is an uncommon central nervous system tumor requiring complete surgical excision for favorable outcome.
  • The authors report the successful treatment of a 2-year-old patient with widely disseminated CPC and Li-Fraumeni syndrome.
  • Following a partial resection of the tumor the patient received chemotherapy consisting of cyclophosphamide, etoposide, and carboplatin.
  • Remarkably, the patient remains without evidence of active disease more than 3 years from the completion of therapy.
  • Additional studies are necessary to determine whether this treatment plan can be beneficial to other patients with CPC and whether the patient's p53 mutation had an effect on outcome.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Choroid Plexus Neoplasms / drug therapy. Li-Fraumeni Syndrome / drug therapy. Neoplasm Metastasis / drug therapy
  • [MeSH-minor] Carboplatin / therapeutic use. Child, Preschool. Cyclophosphamide / therapeutic use. Etoposide / therapeutic use. Female. Humans. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Choroid Plexus Carcinoma.
  • Genetic Alliance. consumer health - Li Fraumeni syndrome.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15654279.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


14. Tenenbaum T, Matalon D, Adam R, Seibt A, Wewer C, Schwerk C, Galla HJ, Schroten H: Dexamethasone prevents alteration of tight junction-associated proteins and barrier function in porcine choroid plexus epithelial cells after infection with Streptococcus suis in vitro. Brain Res; 2008 Sep 10;1229:1-17
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dexamethasone prevents alteration of tight junction-associated proteins and barrier function in porcine choroid plexus epithelial cells after infection with Streptococcus suis in vitro.
  • Apart from antibiotic treatment in bacterial meningitis supportive therapy including dexamethasone is widely used.
  • In investigations on the pathogenesis of bacterial meningitis we previously demonstrated that Streptococcus suis (S. suis), a relevant cause of bacterial meningitis in pigs and humans, affects porcine choroid plexus epithelial cell (PCPEC) barrier function.
  • The choroid plexus epithelium constitutes the structural basis of the blood-CSF barrier.
  • Infection with S. suis leads to an inflammatory response exemplified by the induction of tumor necrosis factor (TNF) alpha and matrix metalloproteinase (MMP)-3 gene activation, which correlated with phosphorylation of extracellular signal regulated kinases (ERKs).
  • [MeSH-major] Anti-Inflammatory Agents / pharmacology. Choroid Plexus / cytology. Dexamethasone / pharmacology. Epithelial Cells. Gene Expression Regulation / drug effects. Membrane Proteins / metabolism. Streptococcaceae / physiology
  • [MeSH-minor] Animals. Capillary Permeability / drug effects. Capillary Permeability / radiation effects. Cell Survival / drug effects. Cell Survival / physiology. Cell Survival / radiation effects. Cells, Cultured. Dose-Response Relationship, Drug. Mannitol / metabolism. Radiation. Signal Transduction / drug effects. Signal Transduction / radiation effects. Swine. Time Factors. Tritium / metabolism

  • Hazardous Substances Data Bank. TRITIUM, RADIOACTIVE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. D-MANNITOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18644352.001).
  • [ISSN] 0006-8993
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Membrane Proteins; 10028-17-8 / Tritium; 3OWL53L36A / Mannitol; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


15. Yano T, Sawaishi Y, Hirayama A, Takaku I, Takada G: Leukoencephalopathy around a tumor cyst following intracystic methotrexate injection. Pediatr Neurol; 2005 Jan;32(1):68-71
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukoencephalopathy around a tumor cyst following intracystic methotrexate injection.
  • A 4-year-old female with choroid plexus carcinoma developed progressive disturbance of consciousness 2 years after postoperative treatment with radiotherapy, chemotherapy, and focal methotrexate injection into a residual tumor cyst.
  • A malignant recurrence of choroid plexus carcinoma with a propensity of cerebrospinal fluid overproduction was suspected.
  • However, daily drainage of cerebrospinal fluid from the cyst and treatment with glycerol and dexamethasone achieved improvement.
  • Diffuse hypoperfusion over the lesions on single-photon emission computed tomography denied the possibility of residual tumor aggravation and together with subsequent atrophic changes confirmed that the lesions reflect localized leukoencephalopathy, possibly associated with methotrexate forced into the parenchyma as a result of the expanding intracystic high pressure.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Choroid Plexus Neoplasms / drug therapy. Choroid Plexus Neoplasms / pathology. Cysts / etiology. Cysts / pathology. Methotrexate / administration & dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15607610.001).
  • [ISSN] 0887-8994
  • [Journal-full-title] Pediatric neurology
  • [ISO-abbreviation] Pediatr. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


16. Nomura Y, Yasumoto S, Yanai F, Akiyoshi H, Inoue T, Nibu K, Tsugu H, Fukushima T, Hirose S: Survival and late effects on development of patients with infantile brain tumor. Pediatr Int; 2009 Jun;51(3):337-41
MedlinePlus Health Information. consumer health - Toddler Development.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival and late effects on development of patients with infantile brain tumor.
  • BACKGROUND: Most infants with brain tumor may have a poor prognosis.
  • The aim of the present study was to retrospectively analyze the survival and outcome with regard to mental and physical development in 11 subjects with brain tumor; these tumors were diagnosed when the patients were under 1 year of age.
  • METHODS: The histological diagnoses of these tumors were astrocytoma, n = 3; pineocytoma, n = 2; teratoma, n = 1; ependymoma, n = 1; atypical teratoid/rhabdoid tumor, n = 1; glioblastoma, n = 1; medulloblastoma, n = 1; and choroid plexus papilloma, n = 1.
  • Surgical resection was performed in eight patients, and adjuvant chemotherapy was administered to all except one patient with choroid plexus papilloma.
  • Radiotherapy was additionally performed for four of the 10 chemotherapy patients.
  • Among the surviving patients, five were under no treatment for 50-167 months after the diagnosis (median duration, 89 months), while one received chemotherapy for 20 months.
  • Five patients exhibited mental retardation, and one patient experienced normal development after surgical removal of his choroid plexus papilloma.
  • Diencephalic syndrome developed in one patient with pilomyxoid astrocytoma that necessitated hormone replacement therapy, and bodyweight over +2 SD was observed in two patients.
  • CONCLUSION: The prognosis of infantile brain tumor with regard to mortality and developmental outcome remains poor.
  • [MeSH-major] Astrocytoma / mortality. Brain Neoplasms / mortality. Child Development. Pinealoma / mortality
  • [MeSH-minor] Chemotherapy, Adjuvant. Female. Humans. Infant. Infant, Newborn. Magnetic Resonance Imaging. Male. Prognosis. Quality of Life. Radiotherapy, Adjuvant

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Infant and Newborn Development.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19400825.001).
  • [ISSN] 1442-200X
  • [Journal-full-title] Pediatrics international : official journal of the Japan Pediatric Society
  • [ISO-abbreviation] Pediatr Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


17. El-Gaidi MA, Eissa EM: Infantile intracranial neoplasms: characteristics and surgical outcomes of a contemporary series of 21 cases in an Egyptian referral center. Pediatr Neurosurg; 2010;46(4):272-82
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the demographic, clinical, radiological, pathological and surgical features and outcomes of infantile intracranial neoplasms, the second most common neoplasm in infants.
  • PATIENTS AND METHODS: We conducted a retrospective study in the Department of Pediatric Neurosurgery at the Abo El-Reish Children's Hospital from 2005 to 2008.
  • The most common tumor was choroid plexus papilloma (23.8%), followed by teratoma (19%) then astrocytoma and ependymoma (14.3% each).
  • Three patients received chemotherapy, but none received radiotherapy.
  • The statistically significant predictors of prognosis were the extent of resection and tumor grade.
  • CONCLUSION: Although the prognosis for infantile intracranial neoplasms is worse than for older children, an overall promising outcome with low operative morbidity and mortality was achieved using gross total excision and appropriate adjuvant chemotherapy as part of a multidisciplinary approach.
  • [MeSH-major] Brain Neoplasms / mortality. Brain Neoplasms / surgery. Papilloma, Choroid Plexus / mortality. Papilloma, Choroid Plexus / surgery
  • [MeSH-minor] Adolescent. Astrocytoma / drug therapy. Astrocytoma / mortality. Astrocytoma / surgery. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Egypt / epidemiology. Ependymoma / drug therapy. Ependymoma / mortality. Ependymoma / surgery. Female. Humans. Infant. Infant, Newborn. Male. Medulloblastoma / drug therapy. Medulloblastoma / mortality. Medulloblastoma / surgery. Morbidity. Neurilemmoma / drug therapy. Neurilemmoma / mortality. Neurilemmoma / surgery. Prognosis. Quality of Life. Referral and Consultation / statistics & numerical data. Retrospective Studies. Teratoma / drug therapy. Teratoma / mortality. Teratoma / surgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 21160236.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


18. Vinchon M, Dhellemmes P: [Third ventricle tumors in children]. Neurochirurgie; 2000 Jun;46(3):323-34

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Particularités pédiatriques des tumeurs du troisième ventricule.
  • Tumors of the third ventricle in children raise specific problems, owing to their clinical presentation, pathology, treatment, and outcome.
  • Some histological types are specific of the pediatric group, such as the pilocytic astrocytoma or hypothalamic hamartoma, and others types which are exceptional in adults are relatively common in children, such as choroid plexus tumors.
  • Chemotherapy has reduced the indication of irradiation, and, in some cases, can be performed preoperatively to reduce tumor volume and intraoperative blood loss.
  • The therapeutic approach to these patients is thus pluridisciplinar, and should be tailored for each case, with a follow-up protracted well into the adult age.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10854989.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] FRANCE
  • [Number-of-references] 60
  •  go-up   go-down


19. Wagner S, Peters O, Fels C, Janssen G, Liebeskind AK, Sauerbrey A, Suttorp M, Hau P, Wolff JE: Pegylated-liposomal doxorubicin and oral topotecan in eight children with relapsed high-grade malignant brain tumors. J Neurooncol; 2008 Jan;86(2):175-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pegylated-liposomal doxorubicin and oral topotecan in eight children with relapsed high-grade malignant brain tumors.
  • BACKGROUND: The combination of topoisomerase I and II chemotherapeutic agents has shown promising preclinical synergistic effects in the treatment of high-grade malignant brain tumors such as high-grade gliomas and choroid plexus carcinomas.
  • To confirm the effectiveness of this treatment combination and determine its possible toxicity, we conducted a retrospective review of the charts of children who received the therapy.
  • METHODS: Patients with relapsed malignant brain tumors who were given an individualized treatment of pegylated (PEG)-liposomal doxorubicin and topotecan were included in our study.
  • The main toxicity (NCI-CTC) after three cycles of the combination therapy was grade IV hematotoxicity (n = 3); grade III hematotoxicity (n = 2), grade III stomatitis (n = 1), grade III infection (n = 2), grade III diarrhea (n = 1); and grade II dermatitis (n = 1).
  • CONCLUSION: The schedule of PEG-liposomal doxorubicin with 30-40 mg/m(2) every 4 weeks in combination with oral topotecan resulted in tumor response, but the toxicity was high.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Administration, Oral. Adolescent. Carcinoma / drug therapy. Carcinoma / pathology. Child. Child, Preschool. Choroid Plexus Neoplasms / drug therapy. Choroid Plexus Neoplasms / pathology. Disease-Free Survival. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Drug Administration Schedule. Drug Eruptions. Hematologic Diseases / chemically induced. Humans. Polyethylene Glycols / administration & dosage. Recurrence. Retrospective Studies. Stomatitis / chemically induced. Topotecan / administration & dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Invest. 1994;12(3):308-13 [8187008.001]
  • [Cites] Cancer. 2004 Mar 15;100(6):1199-207 [15022287.001]
  • [Cites] Cancer. 1994 Mar 1;73(5):1478-84 [8111716.001]
  • [Cites] Int J Oncol. 2003 Jul;23(1):159-63 [12792789.001]
  • [Cites] Drugs. 1998 Nov;56(5):747-56 [9829150.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):413-8 [11839657.001]
  • [Cites] Cancer. 2004 Apr 15;100(8):1750-7 [15073866.001]
  • [Cites] Ann N Y Acad Sci. 2000;922:330-3 [11193915.001]
  • [Cites] Cancer. 2000 Sep 1;89(5):1037-47 [10964334.001]
  • [Cites] J Clin Oncol. 1984 Mar;2(3):207-14 [6321689.001]
  • [Cites] Ann Oncol. 1996 Feb;7(2):205-7 [8777179.001]
  • [Cites] Biochem Pharmacol. 1999 Apr 1;57(7):727-41 [10075079.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):25-36 [11815957.001]
  • [Cites] Anticancer Res. 1999 Mar-Apr;19(2A):941-50 [10368637.001]
  • [Cites] J Neurosurg. 1995 Dec;83(6):1029-37 [7490617.001]
  • [Cites] Semin Oncol. 1998 Oct;25(5 Suppl 12):3-6 [9865704.001]
  • [Cites] Biochim Biophys Acta. 1998 Oct 1;1400(1-3):139-54 [9748545.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7785-91 [11691793.001]
  • [Cites] Drugs. 1997;54 Suppl 4:15-21 [9361957.001]
  • [Cites] Eur J Cancer. 2000 Aug;36(12):1558-64 [10930804.001]
  • [Cites] Cancer. 1999 Mar 1;85(5):1160-5 [10091802.001]
  • [Cites] Cancer. 2001 Oct 1;92(7):1936-42 [11745268.001]
  • [Cites] J Cancer Res Clin Oncol. 1999 Aug-Sep;125(8-9):481-6 [10480340.001]
  • [Cites] Eur J Cancer Clin Oncol. 1982 Feb;18(2):167-76 [7201392.001]
  • [Cites] Cancer. 1996 Aug 1;78(3):527-31 [8697400.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3463-9 [11481351.001]
  • [Cites] Cancer. 2000 Nov 15;89(10):2131-7 [11066055.001]
  • [Cites] Ann Intern Med. 1974 Feb;80(2):249-59 [4590654.001]
  • (PMID = 17641821.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / liposomal doxorubicin; 30IQX730WE / Polyethylene Glycols; 7M7YKX2N15 / Topotecan; 80168379AG / Doxorubicin
  •  go-up   go-down


20. Nejat F, Kazmi SS, Ardakani SB: Congenital brain tumors in a series of seven patients. Pediatr Neurosurg; 2008;44(1):1-8
MedlinePlus Health Information. consumer health - Prenatal Testing.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital brain tumors in a series of seven patients.
  • BACKGROUND: Congenital brain tumors are very rare.
  • METHODS: Seven congenital brain tumors were diagnosed during 5 years.
  • All neuroimaging studies revealed nonhomogenous tumors with cystic and solid components, except for the case with choroid plexus papilloma (CPP).
  • There were three teratomas, one primitive neuroectodermal tumor, one ependymoblastoma and one CPP.
  • One patient died due to complications of chemotherapy and another one due to tumor recurrence 1 year after surgery.
  • CONCLUSIONS: Today, the availability of noninvasive imaging procedures such as computerized tomography scan and magnetic resonance imaging has improved the diagnosis of congenital brain tumors.
  • [MeSH-major] Brain Neoplasms / diagnosis. Fetal Diseases / diagnosis. Prenatal Diagnosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Fetal Health and Development.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel.
  • (PMID = 18097184.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


21. Schniederjan MJ, Shehata B, Brat DJ, Esiashvili N, Janss AJ: De novo germline TP53 mutation presenting with synchronous malignancies of the central nervous system. Pediatr Blood Cancer; 2009 Dec 15;53(7):1352-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] De novo germline TP53 mutation presenting with synchronous malignancies of the central nervous system.
  • We present a case of a 14-year-old male with a germline TP53 mutation who presented with synchronous primitive neuroectodermal tumor and choroid plexus carcinoma.
  • Identification of synchronous brain tumors prompted genetic testing for predisposition to malignancy.
  • Within 5 months of presentation, the child developed widely metastatic alveolar rhabdomyosarcoma.
  • This case identifies a rare, de novo, germline TP53 mutation presenting with synchronous CNS malignancies and exhibiting a more fulminant course than typical cases of Li-Fraumeni syndrome.
  • [MeSH-major] Brain Neoplasms / genetics. Carcinoma / genetics. Choroid Plexus Neoplasms / genetics. Codon, Nonsense. Genes, p53. Germ-Line Mutation. Neoplasms, Multiple Primary / genetics. Neuroectodermal Tumors, Primitive / genetics. Rhabdomyosarcoma, Alveolar / genetics. Rhabdomyosarcoma, Alveolar / secondary
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Cranial Irradiation. Fatal Outcome. Frontal Lobe / pathology. Frontal Lobe / surgery. Humans. Lomustine / administration & dosage. Male. Neoplasms, Unknown Primary / genetics. Radiotherapy, Adjuvant. Spinal Neoplasms / drug therapy. Spinal Neoplasms / radiotherapy. Spinal Neoplasms / secondary. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19711436.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon, Nonsense; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down






Advertisement